NEOS high Volatility towards FDA decision. 10Q:"At March 31, 2017, the Company held $43.7 million in cash and cash equivalents and $10.6 million in short-term investments"."We believe that our existing cash and cash equivalents and short-term investments will be sufficient to fund our anticipated operating requirements for at least the next twelve months"